Tacit Therapeutics
PrivateLast Round
Series A
Mar 9, 2026
Total Funding Raised
$29.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Tacit Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in March 2026.
Tacit Therapeutics is a biotechnology company that develops RNA-targeted treatments to repair mutated genes using its proprietary Splicing-Directed Repair™ technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tacit Therapeutics Comparables
Compare Tacit Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ascidian Therapeutics | 88% | |
| Amber Bio | 84% | |
| Transit Therapeutics, Inc. | 84% |
For institutional investors. Book with your work email.
Tacit Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 9, 2026 | ||||
| Grant | Jan 15, 2024 | ||||
| Series A | Jun 8, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Tacit Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Mitsui Global Investment | Series A |
| Eisai Innovation | Series A |
| Michigan Capital Network | Series A |
| Civilization Ventures | Series A |
| KdT Ventures | Series A |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 49% MoM, reaching 2.6K.
For institutional investors. Book with your work email.
Tacit Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tacit Therapeutics's valuation, stock price, and market status.
Is Tacit Therapeutics a public or private company?
Tacit Therapeutics is a private company.
What is the current stock price of Tacit Therapeutics?
Tacit Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tacit Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tacit Therapeutics worth (valuation)?
Valuation information for Tacit Therapeutics is not publicly available.
Can I buy Tacit Therapeutics stock?
Tacit Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tacit Therapeutics's last funding round?
Tacit Therapeutics's most recent funding round was Series A on March 9, 2026.
Who are the main investors in Tacit Therapeutics?
Key investors in Tacit Therapeutics include National Science Foundation.
Will Tacit Therapeutics IPO soon?
No public IPO plans have been announced for Tacit Therapeutics.
How can I track Tacit Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tacit Therapeutics's shares on secondary markets.